



REMINDER: The updated Assessment Grid will go into effect July 1, 2019. Please remember to update your systems.

Please note there have been 2 minor changes since the WVA's 5/2/19 Operations Committee Meeting in response to payer comments that 1 vaccine code cannot have 2 separate prices assigned to it. As such, the WVA has created a weighted average for vaccine codes 90744 Recombivax HB® and 90686 Influenza.

Thank you.

Email any questions to info@wavaccine.org.

WVA Grid Update as of July 1, 2019

The Washington Vaccine Association voted to approve the [2019/20 assessment grid](#) proposed at its April 25th board meeting. Assessment rates are being reduced by 2% weighted average over the prior grid. A complete list of the changes and percentages is posted on the WVA website as part of the *Washington Vaccine Association Assessment Grid*. **These changes are effective as of July 1, 2019. Please update all systems appropriately.**

This decrease is the second annual decrease in the last two years due to the Association's strong cash position. The modest decrease is also viewed as more favorable over a larger decrease as it should be sustainable in future years and provide the payer community with better predictability in assessment costs.

Analysis of Changes

While most rates are reduced, some are increased to match the relative CDC contract rate. The aggregate of these individual rates times the corresponding estimated doses per brand equals a 2% reduction in total assessment dollars received by WVA. If a payer remitted \$100,000 last year and their basket of doses represented a normal distribution of the total population of payers, then their remittance this year would be \$98,000. This is a reduction in cash from reduced inflows. These total approximately \$1.5MM reduction in cash.

The 5.75 percent weighted increase in CDC contract is realized in the DOH reimbursements as is the agency pass through indirect rate change from 1.2% to 1.4%. and the proposed implementation of a 3% administration charge. These are a reduction in cash through increased outflows. These total approximately \$5.5 million reduction in cash.

Together, these adjustments are estimated to reduce cash by \$7 million within one year.

Washington Vaccine Association Assessment Grid

FOR ALL CLAIMS WITH A DATE OF SERVICE ON OR AFTER JULY 1, 2019.

Please note that this WVA Assessment Grid, effective July 1, 2019, replaces the grid last updated on July 1, 2018. The grid lists vaccines and their corresponding CPT codes that are part of the dosage-based assessment (DBA) process for providers, health insurance carriers, and third party administrators. There are other childhood vaccines (and corresponding CPT codes) that are not included in the DBA process and, therefore, no assessment is needed. The availability of specific vaccine brands are determined by the manufacturer and not all brands of flu vaccine are offered through the Childhood Vaccine Program (CVP).

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change
90620	58160-0976-20 (10 pack – 1 dose syringe)	Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use	Bexsero®	\$159.13	\$170.75	\$151.07	-5.1%
	58160-0976-06 (1 pack – 1 dose syringe)						
90621	00005-0100-10 (10 pack – 1 dose syringe)	Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use	Trumenba®	\$114.58	\$133.62	\$121.49	6.0%
90633	58160-0825-11 (10 pack – 1 dose vial)	Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use	Havrix®	\$24.73	\$32.89	\$22.88	-7.5%
	58160-0825-52 (10 pack – 1 dose syringe)		Vaqta®		\$32.66		
	00006-4095-02 (10 pack – 1 dose syringe)						
	00006-4831-41 (10 pack – 1 dose vial)						
90636	58160-0815-52 (10 pack – 1 dose syringe)	Hepatitis A and hepatitis B vaccine (HepA-HepB), adult dosage, for intramuscular use. (Age 18 only for CVP)	Twinrix®	\$76.58	\$104.00	\$67.29	-12.1%
90647	00006-4897-00 (10 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use	PedvaxHIB®	\$17.27	\$26.23	\$14.73	-14.7%
90648	49281-0545-03 (5 pack – 1 dose vial)	Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use	ActHIB®	\$13.22	\$16.51	\$10.55	-20.2%
	58160-0818-11 (10 pack – 1 dose vial)		Hiberix®		\$10.85		

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change
90651	00006-4119-03 (10 pack – 1 dose vial)	Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use	Gardasil®9	\$175.91	\$217.11	\$198.64	12.9%
	00006-4121-02 (10 pack – 1 dose syringe)						
90670	00005-1971-02 (10 pack – 1 dose syringe)	Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use	Prevnar 13 TM	\$157.97	\$180.05	\$152.78	-3.3%
90680	00006-4047-41 (10 pack – 1 dose tube)	Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use	RotaTeq®	\$77.39	\$82.89	\$78.60	1.6%
	00006-4047-20 (25 pack – 1 dose tube)						
90681	58160-0854-52 (10 pack – 1 dose vial)	Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use	Rotarix®	\$108.62	\$120.95	\$105.59	-2.8%
90696	58160-0812-11 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine and inactivated poliovirus vaccine (DTaP-IPV), when administered to children 4 through 6 years of age, for intramuscular use	Kinrix®	\$48.10	\$52.12	\$46.06	-4.2%
	58160-0812-52 (10 pack – 1 dose syringe)				Quadracel™		
	49281-0562-10 (10 pack – 1 dose vial)						
90698	49281-0510-05 (5 pack – 1 dose vial)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenzae type b, and inactivated poliovirus vaccine, (DTaP-IPV/Hib), for intramuscular use	Pentacel®	\$78.73	\$96.14	\$66.26	-15.8%
90700	49281-0286-10 (10 pack – 1 dose vial)	Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), when administered to individuals younger than seven years, for intramuscular use	Daptacel®	\$23.15	\$30.84	\$20.82	-10.1%
	58160-0810-11 (10 pack – 1 dose vial)		Infanrix®		\$24.71		
	58160-0810-52 (10 pack – 1 dose syringe)						
90702	49281-0225-10 (10 pack – 1 dose vial)	Diphtheria and tetanus toxoids adsorbed (DT) when administered to individuals younger than 7 years, for intramuscular use	DT (pediatric)	n/a	\$54.59	\$59.59	n/a
90707	00006-4681-00 (10 pack – 1 dose vial)	Measles, mumps and rubella virus vaccine (MMR), live, for subcutaneous use	M-M-R®II	\$27.82	\$75.04	\$23.66	-15.0%
90710	00006-4171-00 (10 pack – 1 dose vial)	Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use	ProQuad®	\$158.06	\$214.37	\$146.52	-7.3%
90713	49281-0860-10 (10 dose vial)	Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use	IPOL®	\$17.60	\$33.53	\$15.11	-14.2%

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change
90714	49281-0215-15 (10 pack – 1 dose syringe)	Tetanus and diphtheria toxoids adsorbed (Td), preservative free, when administered to individuals 7 years or older, for intramuscular use	Tenivac®	\$25.34	\$33.83	\$22.98	-9.3%
	49281-0215-10 (10 pack – 1 dose vial)						
	13533-0131-01 (10 pack – 1 dose vial)	Tetanus and diphtheria toxoids (Td) adsorbed when administered to individuals 7 years or older, for intramuscular use	TDVAX™		\$25.12		
90715	58160-0842-11 (10 pack – 1 dose vial)	Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use	Boostrix®	\$42.98	\$41.19	\$35.95	-16.3%
	58160-0842-52 (10 pack – 1 dose syringe)						
	49281-0400-10 (10 pack – 1 dose vial)		Adacel®		\$45.50		
	49281-0400-20 (5 pack – 1 dose syringe)						
90716	00006-4827-00 (10 pack – 1 dose vial)	Varicella virus vaccine (VAR), live, for subcutaneous use	Varivax®	\$106.58	\$129.30	\$116.07	8.9%
90723	58160-0811-52 (10 pack – 1 dose syringe)	Diphtheria, tetanus toxoids, acellular pertussis vaccine, hepatitis B, and inactivated poliovirus vaccine (DTaP-HepB-IPV), for intramuscular use	Pediarix®	\$71.99	\$79.15	\$65.85	-8.5%
90732	00006-4837-03 (10 pack – 1 dose syringe)	Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to individuals 2 years or older, for subcutaneous or intramuscular use	Pneumovax®23	\$64.19	\$100.19	\$62.78	-2.2%
	00006-4943-00 (10 pack – 1 dose vial)						
90734	49281-0589-05 (5 pack – 1 dose vial)	Meningococcal conjugate vaccine, serogroups A, C, Y and W-135, quadrivalent (MCV4 or MenACWY), for intramuscular use	Menactra®	\$115.52	\$122.31	\$105.76	-8.4%
	58160-0955-09 (5 pack – 1 dose vial)		Menveo®		\$130.75		
90744*	00006-4981-00 (10 pack – 1 dose vial)	Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use	Recombivax HB®	\$17.02	\$23.95	\$17.37	5.1%
	58160-0820-52 (10 pack – 1 dose syringe)		Engerix B®	\$16.05	\$23.72		

CPT Code	NDC Code / Packaging	CPT Code Description	Tradename	WVA Assessment Amount per dose as of 7/1/2018	CDC Private Sector Cost/Dose 4/1/19	WVA Assessment Amount per dose as of 7/1/2019	Percent change
2019-2020 Pediatric Influenza Vaccine Assessments							
90686*	19515-0906-52 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	FluLaval Quadrivalent	\$15.13	\$16.82	\$15.13	0.0%
	49281-0419-50 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent	n/a	\$18.31		n/a
90688	49281-0631-15 (10 dose vial)	Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use	Fluzone® Quadrivalent	\$16.62	\$16.94	\$15.34	-7.7%
90672	66019-0306-10 (10 pack- 1 dose sprayer (Intranasal))	Influenza virus vaccine, quadrivalent, live (LAIV4), for intranasal use	FluMist® Quadrivalent	\$21.33	\$23.70	\$21.05	-1.3%
90674	70461-0319-03 (10 pack – 1 dose syringe)	Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5 mL dosage, for intramuscular use	Flucelvax® Quadrivalent	n/a	\$24.05	\$17.42	n/a

***Note: CPT 90744 & 90686 were split on the former grid update and combined on this version to avoid conflicts or confusion on the correct rate. The rate was determined by the weighted average of expected doses.**

Please note the WVA reserves the right to modify the Assessment Grid in effect at any time with Board approval and appropriate notification of payers.